NVG-291
Chronic & Subacute Spinal Cord Injury
Key Facts
About NervGen Pharma
NervGen Pharma is on a mission to transform the treatment of nervous system damage by developing first-in-class drugs that promote repair and functional recovery, moving beyond symptom management. Its core achievement is advancing NVG-291, a potentially best-in-class PTPσ inhibitor, into a Phase 1b/2a trial for spinal cord injury (SCI) with plans for expansion into Alzheimer's and MS. The strategy leverages a deep scientific foundation in neural inhibition mechanisms and is executed by a seasoned leadership team with proven CNS drug development and regulatory expertise. NervGen's approach addresses a vast, underserved market where no disease-modifying regenerative therapies currently exist.
View full company profileAbout NervGen Pharma
NervGen Pharma is on a mission to transform the treatment of nervous system damage by developing first-in-class drugs that promote repair and functional recovery, moving beyond symptom management. Its core achievement is advancing NVG-291, a potentially best-in-class PTPσ inhibitor, into a Phase 1b/2a trial for spinal cord injury (SCI) with plans for expansion into Alzheimer's and MS. The strategy leverages a deep scientific foundation in neural inhibition mechanisms and is executed by a seasoned leadership team with proven CNS drug development and regulatory expertise. NervGen's approach addresses a vast, underserved market where no disease-modifying regenerative therapies currently exist.
View full company profileAbout NervGen Pharma
NervGen Pharma is on a mission to transform the treatment of nervous system damage by developing first-in-class drugs that promote repair and functional recovery, moving beyond symptom management. Its core achievement is advancing NVG-291, a potentially best-in-class PTPσ inhibitor, into a Phase 1b/2a trial for spinal cord injury (SCI) with plans for expansion into Alzheimer's and MS. The strategy leverages a deep scientific foundation in neural inhibition mechanisms and is executed by a seasoned leadership team with proven CNS drug development and regulatory expertise. NervGen's approach addresses a vast, underserved market where no disease-modifying regenerative therapies currently exist.
View full company profileAbout NervGen Pharma
NervGen Pharma is on a mission to transform the treatment of nervous system damage by developing first-in-class drugs that promote repair and functional recovery, moving beyond symptom management. Its core achievement is advancing NVG-291, a potentially best-in-class PTPσ inhibitor, into a Phase 1b/2a trial for spinal cord injury (SCI) with plans for expansion into Alzheimer's and MS. The strategy leverages a deep scientific foundation in neural inhibition mechanisms and is executed by a seasoned leadership team with proven CNS drug development and regulatory expertise. NervGen's approach addresses a vast, underserved market where no disease-modifying regenerative therapies currently exist.
View full company profile